To the full analysis
NeoGenomics stock: growth
NEONeoGenomics reported $727.33M in revenue for fiscal 2025, up 10.1% on the prior year, up 10.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
28.2%
per year from 2006 to 2025, per share 17.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.4% | 22.0% | 28.2% |
| Revenue per share | 6.8% | 13.2% | 17.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $6.48M | −$130K | −$1.09M |
| 2007 | $11.51M | −$3.38M | −$3.16M |
| 2008 | $20.02M | −$1.38M | −$640.09K |
| 2009 | $29.47M | −$2.24M | −$2.46M |
| 2010 | $34.37M | −$3.3M | −$2.97M |
| 2011 | $43.48M | −$1.18M | −$828K |
| 2012 | $59.87M | $65K | −$4.14M |
| 2013 | $66.47M | $2.03M | $216K |
| 2014 | $87.07M | $1.13M | $5.68M |
| 2015 | $99.8M | −$2.54M | $4.18M |
| 2016 | $244.08M | −$6.14M | $13.94M |
| 2017 | $240.25M | −$396K | $4.35M |
| 2018 | $276.74M | $2.64M | $30.48M |
| 2019 | $408.83M | $8.01M | $3.34M |
| 2020 | $444.45M | $4.17M | −$27.64M |
| 2021 | $484.33M | −$8.35M | −$90.87M |
| 2022 | $509.73M | −$144.25M | −$96.88M |
| 2023 | $591.64M | −$87.97M | −$30.71M |
| 2024 | $660.57M | −$78.73M | −$34.04M |
| 2025 | $727.33M | −$108.03M | −$21.78M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2020)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.